- <sup>1</sup> Diagnostics for detection and surveillance of priority
- <sup>2</sup> epidemic-prone diseases in Africa: an assessment of
- <sup>3</sup> testing capacity and laboratory strengthening needs.
- 4
- 5 Aytenew Ashenafi<sup>1\*</sup>, Olajumoke Sule<sup>2</sup>, Trevor Peter<sup>3</sup>, Silver Mashate<sup>4</sup>, Osborn
- 6 Otieno<sup>5</sup>, Abebaw Kebede<sup>1</sup>, John Oio<sup>1</sup>, Kekeletso Kao<sup>6</sup>, Jane Carter<sup>7</sup>, Toni Whistler<sup>5</sup>,
- 7 Nqobile Ndlovu<sup>4</sup>, Yenew Kebede<sup>1</sup>
- 8 <sup>1</sup>Centre of Laboratory Systems Division, Africa Centres for Disease Control and
- 9 Prevention, Addis Ababa, Ethiopia.
- <sup>10</sup> <sup>2</sup>International Health Regulations Strengthening Project, Health Protection
- 11 Operations, United Kingdom Health Security Agency, London, United Kingdom.
- <sup>12</sup> <sup>3</sup>Clinton Health Access Initiative, Boston, Massachusetts, United States of America.
- <sup>13</sup> <sup>4</sup>African Society for Laboratory Medicine, Addis Ababa, Ethiopia.
- <sup>14</sup> <sup>5</sup>Technical Advice and Partnerships Department, The Global Fund to Fight AIDS,
- 15 Tuberculosis and Malaria, Geneva, Switzerland.
- <sup>16</sup> <sup>6</sup>Diagnostic System Strengthening Unit, FIND , Geneva, Switzerland.
- <sup>17</sup> <sup>7</sup>Clinical and Diagnostics Programme, Amref Health Africa, Nairobi, Kenya.
- 18
- 19 \*Corresponding author
- 20 E-mail: <u>AytenewA@africacdc.org</u> (AA) NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 21 Abstract

In 2023, Africa experienced 180 public health emergencies, of which 90% were 22 infectious diseases and 75% were related to zoonotic diseases. Testing capacity for 23 epidemic-prone diseases is essential to enable rapid and accurate identification of 24 causative agents, and for action to prevent disease spread. Moreover, testing is 25 pivotal in monitoring disease transmission, evaluating public health interventions, and 26 informing targeted resource allocation during outbreaks. An online, self-assessment 27 survey was conducted in African Union Member States to identify major challenges in 28 29 testing for epidemic-prone diseases. The survey assessed current capacity for diagnosing priority epidemic-prone diseases at different laboratory levels. It explored 30 challenges in establishing and maintaining testing capacity to improve outbreak 31 response and mitigate public health impact. Survey data analysed diagnostic 32 33 capacity for priority infectious diseases, diagnostic technologies in use, existing surveillance programmes and challenges limiting diagnostic capacity, by country. The 34 survey result from 15 Member States who responded to the survey, showed high 35 36 variability in testing capacity and technologies across countries and diverse factors limiting testing capacity for certain priority diseases like dengue and Crimean-Congo 37 haemorrhagic fever. At the same time, there is better diagnostic capacity for 38 39 coronavirus disease 2019 (COVID-19), polio, and measles due to previous investments. Unfortunately, many countries are not utilising multiplex testing, despite 40 its potential to improve diagnostic access. The challenges of limited laboratory 41 capacity for testing future outbreaks are indeed significant. Recent disease outbreaks 42 in Africa have underscored the urgent need to strengthen diagnostic capacity and 43 introduce cost-effective technologies. Small sample sizes and differing disease 44 prioritisation within each country limited the analysis. These findings suggest the 45

benefits of evaluating laboratory testing capacity for epidemic-prone diseases and
highlight the importance of effectively addressing challenges to detect diseases and
prevent future pandemics.

49

## 50 Introduction

In 2023, Africa has documented more than 168 public health events affecting 45 51 African Union Member States mostly infectious disease outbreaks including mpox, 52 diphtheria, dengue, Lassa fever, measles, polio, Rift Valley fever and cholera. These 53 outbreaks continue to expand rapidly and affect many countries on the continent. 54 Since the beginning of 2024, a total of 26,122 cholera cases (3,396 confirmed; 55 22,726 suspected) with 663 deaths were reported from 12 African countries; 4,451 56 cases of measles (178 confirmed; 4,273 suspected) and 51 deaths were reported 57 from seven African countries; and for diphtheria 1.573 cases were reported (904 58 confirmed; 669 suspected) with four deaths from two African countries (1-4). 59 The International Health Regulations (IHR, 2005) identify disease mapping, health 60 risk assessment and resource prioritisation as among the core capabilities of public 61 health emergency preparedness and response systems (5). Recurrent outbreaks of 62 emerging and re-emerging pathogens have revealed major gaps in these systems in 63 countries on the African continent. Key mechanisms to prevent recurrent disease 64 outbreaks include early detection of infectious diseases in the community, rapid 65 pathogen identification, and integrated disease surveillance. Surveillance and 66 response capacity is limited in many African countries, especially in the context of 67 COVID-19, Ebola virus disease (EVD), and in detection and monitoring of 68 antimicrobial resistance (6). As the recent EVD, COVID-19 and mpox outbreaks 69

highlight, a major paradigm shift is required to establish effective infrastructure and
 mechanisms for outbreak detection, and common frameworks for preparedness and
 national public health responses to manage future epidemics (7).

73 The Africa Centres for Disease Control and Prevention (Africa CDC) has drawn up a preliminary list of priority epidemic-prone diseases for Africa using a risk ranking and 74 analysis tool to identify the target infectious diseases for epidemic preparedness and 75 76 response actions (8), and to inform research and technology development and disease control innovations such as development and provision of vaccines, 77 diagnostics, and therapeutics. For example, EVD, cholera and COVID-19 scored the 78 79 highest for disease severity, risk and epidemic potential, as well as the need for preparedness through vaccine availability, and medical and non-medical 80 countermeasures. The disease ranking processes changes every time as more 81 evidence comes in. 82

83 The ability to respond effectively to disease outbreaks depends on several factors, including laboratory capacity, a trained health workforce, and robust surveillance 84 systems (9), which are public health systems that rapidly diagnose and contain the 85 spread of infectious diseases. While significant diagnostic capacity has been 86 established over the past two decades for major endemic diseases such as 87 HIV/AIDS, tuberculosis (TB), malaria and more recently COVID-19, testing capacity 88 for other epidemic-prone infections is more limited. Therefore, a comprehensive 89 approach is needed to address the gaps in pandemic preparedness and health 90 systems' resilience (10, 11). 91

The Africa CDC undertook a survey of African Union Member States on disease
 priorities, laboratory capacities and public surveillance systems to help identify major
 challenges faced in building testing capacity for outbreak detection and response for

95 epidemic-prone diseases in African countries. The findings of this survey are

96 presented in this paper.

97

### 98 Methods

#### 99 Survey description

All 55 African Union Member States were invited to participate in a self-assessment survey of laboratory testing capacity and surveillance of 22 epidemic-prone diseases between February and April 2023. These diseases were selected through a risk ranking and prioritisation exercise undertaken by Africa CDC in collaboration with the European Centre for Disease Prevention and Control in 2022 (8).

#### **105** Survey instrument

The survey instrument was developed and validated in consultation with members of the Africa Laboratory Technical Working Group (S1 questionnaire file). It included questions on disease testing capacity, technology in use, healthcare system level and presence of surveillance programmes. Additionally, questions addressed multiplex testing capacity and challenges faced.

111 Participants were asked to rank their capacity to diagnose the priority epidemic-prone

diseases (S2 list file) on a five-point Likert scale (from 1–5), with 5 being the highest.

- 113 Quantitative questions included information on disease testing capacity across
- 114 countries' healthcare systems, standard methods used to diagnose diseases (PCR,
- 115 multiplex PCR, lateral flow assays, ELISA, etc.), biosecurity, sample transport, data
- systems, staffing and existing surveillance programmes. Qualitative questions were

also included to allow respondents to add relevant comments, and to identify
countries' most significant challenges and the support needed to ensure adequate
diagnostic capacity for future outbreaks and epidemics. The survey tool was
developed in a Microsoft Excel format using dropdown lists to make it user-friendly.
The tool was provided in English and French, pre-tested, amended and distributed
online to respondents (S1 questionnaire file).

123 The first section of the survey comprised 8- questionnaire for disease testing capacity to correlate the epidemic-prone disease to the capacity of diagnosis and technology 124 in use and surveillance programmes for these diseases. The respondent only 125 126 completes the boxes. Some of these boxes have a dropdown menu so that they can only select answers. The tool allows countries to add a comment describing their 127 testing method and asking about the standard methods used to diagnose diseases 128 (PCR, Multiplex PCR, Lateral Flow Assay, ELISA, and others). Based on the 129 responses, the ability to diagnose the twenty-two priority epidemic-prone diseases 130 were rated on a five-point scale from 1 to 5, with 5 representing the highest score... 131 132 The second survey has 3-questionnaire for multiplex testing capacity and panel of multiplex testing, and levels of laboratory testing capacity across Member States' 133 healthcare systems. 134

The third survey has 8-miscellaneous and 3-qualitative questionnaires on sample transport, biosecurity, data systems and staffing. Some qualitative questions were included to get a general sense of the support countries need/want and explore countries' biggest challenges to ensuring diagnostic capacity to be ready for a future epidemic.

140

## 141 Dissemination of the survey tool to countries and data

### 142 collection

- 143 All African countries were invited to participate in the survey, targeting national public
- 144 health laboratory directors, managers and heads of reference laboratories. We
- collected the informed consent form from online survey links obtained from a network
- of laboratories that got a request to participate in a survey. Data were collected from
- 147 February to April 2023.

148

## 149 Data entry and analysis

150 Data were entered into SPSS 2023 and Excel for data analysis and visualisation.

# 151 Ethics Considerations

- 152 Ethics approval was not sought for the following reasons.
- 153 The survey pertained to member state diagnostic capacity did not include data on
- individual patients or vulnerable people. The survey instrument was developed in
- 155 consultation with members of Africa CDC Laboratory Technical Working
- 156 Group. Participation by member states was voluntary following informed
- 157 consent. Responses were stored securely on Africa CDC platform and published
- results of the survey Responses were via online methodology and results of the
- 159 survey are anonymised and cannot be traced to member states.

160

# 161 Results

# 162 Survey respondents

- 163 Participants from 15 of 55 (27%) Member States responded to the survey (Fig 1).
- 164 Respondents were distributed as follows: five (50%) from the southern region, four
- (27%) from the western region, three (21%) from the eastern region, two (29%) from
- the northern region, and one (11%) from the central region. The survey was
- 167 completed by laboratory directors (7) and senior technical staff members (8) working
- at either national public health institutes (12) or ministries of health (3).



169



171

### 172 Disease testing capacity by laboratory level

- 173 Capacity for diagnosing infectious diseases varied based on the disease, country and
- 174 laboratory level (Fig 2). Testing for viral haemorrhagic fevers was conducted at
- 175 central public health laboratories and tertiary care hospital laboratories, while testing

- 176 for COVID-19, meningococcal meningitis, cholera, measles and dengue was
- 177 conducted at laboratories ranging from reference to district level.



Fig 2. Stacked bar graph showing the percentage of countries (n=15) that can
 test for the specified priority epidemic-prone disease at each tier of the
 laboratory system.

182

The most common testing technology reported for diagnosing causative agents of epidemic-prone diseases was real-time polymerase chain reaction (qPCR) followed by enzyme-linked immunosorbent assay (ELISA). There were differences in testing capacity and technology across the participating countries. All 15 countries reported use of PCR testing for COVID-19. Measles and mpox were the next most common diseases diagnosed by PCR. Among Member States using PCR for testing, opensource instruments were available in 60% of national public health laboratories, 47%

of regional and tertiary laboratories, and 20% of secondary care laboratories. ELISA 190 was routinely performed to diagnose seven diseases (measles, yellow fever, CCHF, 191 Rift Valley fever, dengue, Zika and chikungunya) across eleven countries, with 192 measles being the most common. Among bacterial infections, few countries reported 193 using molecular techniques for diagnosis, with between one and three countries each 194 reporting molecular techniques for diagnosing cholera, plague, anthrax, and 195 meningococcal disease. Two countries reported conducting culture for diagnosing 196 cholera, plague, and meningococcal disease. Some countries did not report 197 diagnostic capacity for testing certain infections. Eleven of the 15 countries did not 198 199 test for anthrax, and ten countries did not perform testing for plague and rabies due to lack of capacity. 200

201

#### 202 Surveillance programmes for priority infectious diseases

The three most common surveillance programmes that countries were actively 203 running during the survey were COVID-19, measles, and polio (Fig 3). Twelve 204 205 countries reported having surveillance programmes for between three and twelve priority diseases. Several countries reported both the availability of PCR testing and 206 the presence of surveillance programmes for some priority diseases, for example, 207 208 plague, anthrax, cholera and meningitis. For polio, ten countries reported having surveillance programs, but only six countries indicated they have PCR diagnostic 209 210 capacity.



211

212 Fig 3. Number of countries reporting capacity for laboratory diagnosis (PCR

and/or ELISA) of the priority epidemic-prone diseases and current active

- 214 surveillance systems.
- 215

# 216 Epidemic-prone disease priorities for diagnosis and

#### 217 surveillance

- 218 There were large differences in countries' priorities for disease diagnosis and
- surveillance. Thirteen countries reported COVID-19 as the highest priority for their
- 220 country, whereas two countries reported dengue fever as their highest priority. Others
- reported avian influenza, plague, anthrax, respiratory syncytial virus (RSV) disease,

chikungunya, and EVD as their priority. There were disparities between priority and
the capacity to diagnose diseases. For example, while COVID-19 was reported to be
a high-priority disease with high diagnostic capacity among countries, four countries
reported polio as a high-priority disease but with low diagnostic capacity using the
Likert scale 1-5 for both capacity to diagnosis and priority (Fig 4).



Fig 4. Self-reported testing capacity against the country priority for each

survey. Blue marker represents viral diseases, and the orange marker designates

epidemic-prone disease across the 15 Member States participating in the

bacterial diseases. Inputs were provided on a Likert scale (1-5, with 5 being the

highest priority), the average scores across reporting countries for the pathogen are

233 plotted.

# Need for laboratory multiplexing testing capacity.

- 235 Most respondents indicated the need for multiplex diagnostic testing capacity for
- 236 infectious respiratory illnesses and arbovirus infections followed by meningitis (Table
- 1). For some diseases, the perceived need was less commonly reported.

#### Table 1. Number of countries reporting the need for multiplex testing by

239 disease and/or pathogens.

Diseases (pathogens) for which multiplex testing was	Number of countries
reported as most needed	n=14 (%)
Infectious respiratory Illness (influenza virus, RSV, SARS-	11 (79%)
CoV-2)	11 (1070)
Arbovirus (dengue, chikungunya, Zika, yellow fever, Rift	0 (0 40( )
Valley fever, West Nile viruses, encephalitis)	9 (64%)
Meningitis (including Neisseria meningitidis, Streptococcus	7 (50%)
pneumoniae)	
Diarrhoeal illness including cholera	3 (21%)
Viral haemorrhagic fevers (including CCHF virus, Marburg	3 (21%)
virus, Lassa virus)	0 (2170)

240

# 241 Reported challenges limiting diagnostic capacity for future

## 242 epidemics

- 243 Eighty-five per cent of countries that responded to the survey cited inconsistent
- 244 laboratory supplies such as PCR reagents, extraction kits and consumables as the
- primary challenge to developing laboratory capacity to diagnose future epidemics.

- This was followed by inadequate infrastructure (45%), limited government funding
- 247 (43%), inadequate equipment management (35%) and inadequate human resources
- 248 (25%) (Fig 5).



#### **Fig 5. Reported gaps in laboratory diagnostics capacity limiting support for**

- 251 **future epidemics.**
- 252

249

## 253 Discussion

The survey aimed to understand countries' laboratory diagnostic needs for epidemic 254 preparedness and response. The results offered insights into existing laboratory 255 capacity for priority epidemic-prone diseases across 15 countries. They provided an 256 257 overview of the capacity within functional tiered laboratory networks across various African Union Member States. These capacities are crucial for implementing the IHR 258 and addressing urgent public health threats such as COVID-19, EVD, measles, 259 260 CCHF, and others. In recent years, the Africa region has experienced a surge in outbreaks and 261 epidemics, threatening the health of populations and socio-economic stability, with 262

263 potential global ramifications (12). Reported disease outbreaks include yellow fever,

Rift Valley fever, mpox, measles, CCHF, dengue fever, chikungunya, EVD, Marburg virus disease, cholera, diphtheria, and COVID-19. However, Africa's inadequate disease diagnosis and surveillance systems hinder the prediction, prevention and effective management of emerging infectious diseases (13). Delayed detection of outbreaks is attributed to a lack of real-time surveillance, suboptimal laboratory networks, limited diagnostic capabilities, inadequate resources, and insufficient technical and managerial capacities.

This survey showed that the capacity for diagnosing infectious diseases varied by 271 disease, country, and laboratory level within tiered networks. The most common 272 technology for diagnosing epidemic-prone diseases was PCR, followed by ELISA. All 273 15 participating countries reported the use of PCR testing for COVID-19, highlighting 274 the improvements in diagnostics from the COVID-19 pandemic. In contrast, priority 275 diseases such as polio and plague had limited PCR testing capacity. These results 276 may reflect differing country priorities, levels of laboratory testing maturity, and/or the 277 278 availability of national and external funds to diagnose priority pathogens. The findings suggest that policy and decision-makers have shown a consistent commitment to 279 improving laboratory capacity and system development, as demonstrated by the high 280 281 capacity to diagnose COVID-19; however, our assessment has also uncovered significant deficiencies in disease diagnostic capacity, particularly at different levels of 282 the tiered laboratory networks that handle epidemic-prone diseases. 283

Lower-level laboratories exhibited weaknesses in testing for diseases such as Rift Valley fever, CCHF, plague, dengue fever and Zika, which were predominantly conducted at central and regional laboratories, compared to their capabilities for diagnosing COVID-19, polio, measles, mpox, cholera and meningitis. This disparity reflects historical prioritisation and investment in testing for specific diseases,

technological advancements, biosafety concerns, and the diversity and availability of 289 290 funding resources. The COVID-19 crisis underscores the world's historical unpreparedness to detect and respond to emerging infectious diseases (14). Recent 291 292 outbreaks of diseases such as Lassa fever, EVD, Marburg virus disease, diphtheria, anthrax, and cholera across the continent highlight the urgent need to strengthen 293 294 diagnostic capacity for emergency response and outbreak management. Lassa 295 fever's expanding geographical spread in West Africa underscores the evolving epidemiology of infectious diseases and the necessity for all countries to possess 296 resilient and adaptable diagnostic capabilities (15). 297

298 Inadequate diagnostic testing remains a significant issue in African countries (16, 17), particularly at lower-level laboratories. Many commercially available diagnostic tools 299 do not meet the needs of these laboratories or cannot be used due to weak 300 infrastructure. Increased investment in testing capacity at lower-level laboratories is 301 crucial, along with developing and implementing appropriate technologies for 302 303 diagnosing epidemic-prone diseases. Some tests are available in multiplex format, enabling the detection of multiple pathogens in a single sample for both surveillance 304 and clinical management purposes. Establishing diagnostic capacity for priority 305 306 diseases of epidemic potential through integrated testing within existing laboratory capacity and with multiplex testing will improve epidemic preparedness, aid early 307 detection and response, and help prevent outbreaks from becoming pandemics (18, 308 19). 309

Limited access to diagnostic testing has been a bottleneck in the early detection of priority diseases in Africa (20-22). Diagnostic capacity has often focused on diseases such as HIV, TB, malaria, and more recently, COVID-19 (23, 24). However, laboratories and health systems established for these infections can also be used to

detect other priority diseases of epidemic potential, thereby expanding the range of
 pathogen detection capacity in African Union Member States using existing
 methodologies.

This survey highlights that the effectiveness of response measures is impeded by various factors, including limited laboratory capacities, difficulties in accessing diagnostic services, shortages of human resources, and fragmented surveillance systems. These challenges exacerbate the complexities of response efforts in numerous countries within the Africa region. The integration of testing and effective use of existing diagnostic platforms and laboratory infrastructure were demonstrated with SARS-CoV-2 testing during the COVID-19 pandemic.

The limitations of this survey included reliance on self-reporting and the limited number of countries that responded. Despite these limitations, the survey results provided valuable insights into diagnostic capacity, disease priorities, surveillance systems and current challenges to the diagnosis of epidemic-prone diseases and has highlighted gaps that urgently need to be addressed to enhance epidemic preparedness, facilitate early disease detection and response, and mitigate the risk of outbreaks escalating into pandemics.

## 331 Conclusion

The increased technical capacity for diagnosing infectious diseases since the COVID-19 epidemic is evident. With ongoing outbreaks of diseases such as yellow fever, Rift Valley fever, mpox, measles, CCHF, dengue fever, chikungunya, EVD, Marburg virus disease, cholera and diphtheria across the continent, there is an urgent need to address the gaps in diagnostic capacity and disease surveillance. Recognising the varying country priorities, expanding point-of-care and multiplex

testing for syndromic disease surveillance, and monitoring changes in epidemiology
are crucial steps to enhance readiness for detecting epidemic-prone diseases.
Countries need to prioritise rapid diagnostic tests and portable technologies while
strengthening national and regional laboratory networks. This requires updating
infrastructure, improving the laboratory supply chain, and investing in staff training
and development.

# 344 Acknowledgements

We express our gratitude to the Ministry of Health of participated countries and to the numerous colleagues at our respective institutions who have engaged in discussions, provided valuable input, and offered feedback on the paper. Their contributions have significantly enhanced the quality of the final manuscript. The authors would like to express their gratitude to Africa Laboratory Technical Working Group (AfLTWG) members. The contents of this paper are solely the responsibility of the authors.

# 351 Supporting information

- 352 S1 laboratory capacity questionnaire (XLS)
- 353 S2 list of epidemic-prone diseases (DOCX)

# 354 References

- 1. World Economic Forum. Building resilient healthcare systems in Africa with a
- focus on outbreaks and epidemics. 2023. Available from:
- 357 https://www.weforum.org/agenda/2023/07/building-resilient-healthcare-
- 358 systems-in-africa-with-a-focus-on-outbreaks-and-epidemics/

359	2.	Moyo E, Mhango M, Moyo P, Dzinamarira T, Chitungo I, Murewanhema G.
360		Emerging infectious disease outbreaks in Sub-Saharan Africa: Learning from
361		the past and present to be better prepared for future outbreaks. Front Public
362		Health. 2023;11:1049986.
363	3.	Africa Centres for Disease Control and Prevention. Building Testing Capacity
364		for Epidemic-Prone Diseases. 2023. Available from:
365		https://africacdc.org/download/building-testing-capacity-for-epidemic-prone-
366		diseases
367	4.	Africa Centres for Disease Control and Prevention. Disease Outbreaks:
368		Information on disease outbreaks from Africa CDC [Internet]. [cited November
369		2023]. Available from: https://africacdc.org/disease-outbreak/.
370	5.	Hayman DTS, Barraclough RK, Muglia LJ, McGovern V, Afolabi MO, N'Jai AU,
371		et al. Addressing the challenges of implementing evidence-based prioritisation
372		in global health. BMJ Glob Health. 2023;8(6).
373	6.	Adebisi YA, Rabe A, Lucero-Prisno III DE. COVID-19 surveillance systems in
374		African countries. Health Promot Perspect. 2021;11(4):382-92.
375	7.	Aborode AT, Hasan MM, Jain S, Okereke M, Adedeji OJ, Karra-Aly A, et al.
376		Impact of poor disease surveillance system on COVID-19 response in Africa:
377		Time to rethink and rebuilt. Clin Epidemiol Glob Health. 2021;12:100841.
378	8.	Africa Centres for Disease Control and Prevention. Risk Ranking and
379		Prioritization of Epidemic-Prone Diseases. 2023. Available from:
380		https://africacdc.org/download/risk-ranking-and-prioritization-of-epidemic-
381		prone-diseases/

382	9.	Nachega JB, Nsanzimana S, Rawat A, Wilson LA, Rosenthal PJ, Siedner MJ,
383		et al. Advancing detection and response capacities for emerging and re-
384		emerging pathogens in Africa. Lancet Infect Dis. 2023;23(5):e185-e9.
385	10.	Ewert B, Wallenburg I, Winblad U, Bal R. Any lessons to learn? Pathways and
386		impasses towards health system resilience in post-pandemic times. Health
387		Econ Policy Law. 2023;18(1):66-81.
388	11.	Rajapaksha R, Khatri RB, Abeysena C, Wijesinghe MSD, Endalamaw A,
389		Thomas TK, et al. Success and challenges of health systems resilience-
390		enhancing strategies for managing Public Health Emergencies of International
391		Concerns (PHEIC): A systematic review protocol. BMJ Open.
392		2022;12(11):e067829.
393	12.	In: Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, et
394		al., editors. Disease Control Priorities: Improving Health and Reducing
395		Poverty. Washington (DC): The World Bank. 2017. Available from:
396		https://www.ncbi.nlm.nih.gov/books/NBK525302/
397	13.	Nyaruaba R, Okoye CO, Akan OD, Mwaliko C, Ebido CC, Ayoola A, et al.
398		Socio-economic impacts of emerging infectious diseases in Africa. Infect Dis
399		(Lond). 2022;54(5):315-24.
400	14.	Craven M, Sabow A, Van der Veken L, Wilson M. Not the last pandemic:
401		Investing now to reimagine public-health systems2021. Available from:
402		https://www.mckinsey.com/industries/public-sector/our-insights/not-the-last-
403		pandemic-investing-now-to-reimagine-public-health-systems.
404	15.	Balogun OO, Akande OW, Hamer DH. Lassa Fever: An Evolving Emergency
405		in West Africa. Am J Trop Med Hyg. 2020;104(2):466-73.

406	16.	Brehm B. The case for investment: Insights from five African manufacturers on
407		local manufacturing of diagnostic tools2023. Available from:
408		https://www.path.org/our-impact/articles/investment-insights-local-
409		manufacturing-diagnostic/.
410	17.	The Global Fund. Results Report 2023. Geneva, Switzerland: The Global
411		Fund; 2023 Available from:
412		https://www.theglobalfund.org/en/results/#download.
413	18.	Ramos PIP, Marcilio I, Bento AI, Penna GO, de Oliveira JF, Khouri R, et al.
414		Combining Digital and Molecular Approaches Using Health and Alternate Data
415		Sources in a Next-Generation Surveillance System for Anticipating Outbreaks
416		of Pandemic Potential. JMIR Public Health Surveill. 2024;10:e47673.
417	19.	Calderaro A, Piccolo G, Chezzi C. The Laboratory Diagnosis of Malaria: A
418		Focus on the Diagnostic Assays in Non-Endemic Areas. Int J Mol Sci.
419		2024;25(2).
420	20.	African Society for Microbiology. Bringing diagnostic testing closer to
421		communities. Lab Culture. 2022. Available from: https://aslm.org/wp-
422		content/uploads/2022/06/ASLM_Lab_Culture_Issue_27.pdf
423	21.	Kobia F, Gitaka J. COVID-19: Are Africa's diagnostic challenges blunting
424		response effectiveness? AAS Open Res. 2020;3:4.
425	22.	Heidt B, Siqueira WF, Eersels K, Diliën H, van Grinsven B, Fujiwara RT, et al.
426		Point of Care Diagnostics in Resource-Limited Settings: A Review of the
427		Present and Future of PoC in Its Most Needed Environment. Biosensors
428		(Basel). 2020;10(10).

- 429 23. Mfuh KO, Abanda NN, Titanji BK. Strengthening diagnostic capacity in Africa
- 430 as a key pillar of public health and pandemic preparedness. PLOS Glob Public
- 431 Health. 2023;3(6):e0001998.
- 432 24. Chanda-Kapata P, Ntoumi F, Kapata N, Lungu P, Mucheleng'anga LA,
- 433 Chakaya J, et al. Tuberculosis, HIV/AIDS and Malaria Health Services in sub-
- 434 Saharan Africa A Situation Analysis of the Disruptions and Impact of the
- 435 COVID-19 Pandemic. Int J Infect Dis. 2022;124 Suppl 1:S41-s6.

	Pathogen		Central / Regional Reference	Tertiary Hospital	Secondary Hospital	Primary Care Hospital
	type	Name				
5	Bacterium	Plague	26	0	0	0
10	Bacterium	Meningococcal disease	20	13	26	13
12	Bacterium	Cholera	33	13	13	6
4	Bacterium	Anthras	26	6	0	0
13	Virus	Zika	33	13	13	0
60	Virus	Yellow fever	60	0	6	0
16	Virus	Rift Valley fever	40	6	6	0
7	Virus	Respiratory syncytial virus	20	13	13	0
11	Virus	Rabies	33	0	0	0
2	Virus	Poliovirus	40	6	•	0
1	Virus	Mpax	50	20	0	0
- 3	Virus	Measles	50	13	6	13
17	Virus	Marburg virus	33	13	13	0
18	Virus	Lassa fever	26	6	0	0
8	Virus	Influenza	40	6	20	0
20	Virus	Ebola (Ziare)	50	6	0	0
19	Virus	Ebola (Sudan)	50	6	0	0
21	Virus	Dengue fever	33	13	6	13
22	Virus	Crimean-Congo hemorrhagic fever	33	0	0	0
9	Virus	COVID-19	20	13	20	73
15	Virus	Chikungunya	33	13	6	0
6	Virus	Avian Influenza	33	6	6	0

Percentage of facilities at each tier of the laboratory network that had the ability to test for the specifiec



	Pathogen type	Disease	PCR	ELISA	Surveillance
5	Bacterium	Plague	5	0	5
10	Bacterium	Meningococcal disease	9	0	9
12	Bacterium	Cholera	8	0	8
4	Bacterium	Anthrax	5	0	5
13	Virus	Zika	6	3	5
14	Virus	Yellow fever	9	4	6
16	Virus	Rift Valley fever	6	1	3
7	Virus	Respiratory syncytial virus	6	0	5
11	Virus	Rables	5	0	6
2	Virus	Poliovirus	6	0	10
1	Virus	Mpox	12	0	7
3	Virus	Measles	11	10	11
17	Virus	Marburg virus	7	0	4
18	Virus	Lassa fever	7	0	3
8	Virus	Influenza	9	0	8
20	Virus	Ebola (Ziare)	7	0	5
19	Virus	Ebola (Sudan)	7	0	5
21	Virus	Dengue fever	9	3	8
22	Virus	Crimean-Congo hemorrhagic fever	6	1	3
9	Virus	COVID-19	15	0	12
15	Virus	Chikungunya	7	2	4
6	Virus	Avian Influenza	6	0	5



				No	Total Likert	Diagnostic	Number	Priority	Disease	
				Countries	Dx	capability	Countries		Priority	
	Pathogen type	Pathogen (Disease)	Pathogen (Disease)		capability					
3	Virus	Avian Influenza	Avian Influenza	7	26	3.7	10	32	3.2	
15	Bacterium	Bacillus anthracis (anthrax)	Bacillus anthracis	7	22	3.1	50	38	3.8	
2	t Virus	Chikungunya virus	Chikungunya virus	9	38	4.2	10	38	3.8	
4	Virus	CDHF virus	Crimean-Congo hemorrhagic fever	7	19	2.7	6	18	3.0	
5	Virus	Dengue virus (dengue fever)	Dengue virus	10	29	2.9	9	24	2.7	
6	i Virus	Ebola virus [species Sudan] (Ebola v	Ebola virus (species Sudan)	9	27	3.0	9	31	3.4	
7	Virus	Ebola virus [species Zaire] (Ebola vir	Ebola virus (species Zaire)	9	29	3.2	9	36	4.0	
1	Virus 1	Influenza virus	Influenza virus	10	35	3.5	12	48	4.0	
- 5	Virus	Lassa fever virus	Lassa fever virus	9	28	3.1	8	24	3.0	
30	Virus	Marburg virus	Marburg virus	*	25	3.1	7	22	3.1	
11	Virus	Measles virus	Measles virus	12	48	4.0	3.2	53	4.4	
12	t Virus	Monkeypox virus (mpox)	Monkeypax virus	13	47	3.6	13	54	4.2	
21	Bacterium	Neisseria meningitidis (meningocoo	Nelsseria meningitidis	11	35	3.2	12	54	4.5	
13	Virus .	Poliovirus	Poliovirus		22	2.8	50	47	4.7	
34	Virus	Rabies virus	Rabies virus	7	22	3.1	9	38	4.2	
15	Virus	Respiratory syncytial virus	Respiratory syncytial virus	8	25	3.1	9	28	3.1	
36	i Virus	Rift Valley fever virus	Rift Valley fever virus		25	3.1	8	24	3.0	
3	Virus	SARS-CoV2 (COVID-19)	SARS-CoV2	14	64	4.6	14	67	4.8	
20	Bacterium	Vibrio cholerae (cholera)	Vibrio cholerae	11	-45	3.7	50	41	4.1	
17	Virus .	Yellow fever virus	Yellow fever virus	10	32	3.2	10	37	3.7	
22	Bacterium	Yersinia pestis (Plague)	Yersinia pestis	7	18	2.6	9	27	3.0	
38	Virus .	Zika virus	Zika virus	9	23	2.6	9	24	2.7	



Disease	Priority 5	Priority 4	Priority 3	Priority 2	Priority 1
Dengue Fever	1	1	3	2	2
Avian Influenza	2	2	3	2	1
Crimean Congo Haemorraghic Fever (CCHF)	2	1	0	1	2
Marburg Virus	2	2	0	1	2
Plague	2	0	4	2	1
Respiratory Synctial Virus	2	1	3	2	1
Zika	2	0	3	1	3
Lassa Fever	3	1	0	1	3
Rift Valley Fever	3	1	0	1	3
Ebola (Sudan)	4	1	1	1	2
Rabies	4	3	2	0	0
Anthrax	5	1	2	1	1
Chikungunya	5	1	2	1	1
Influenza	5	3	3	1	0
Cholera	6	1	2	0	1
Ebola (Zaire)	6	0	1	1	1
Measles	8	2	1	1	0
Monkeypox	8	1	2	2	0
Neisseria meningitis	8	2	2	0	0
Poliovirus	9	0	0	1	0
COVID-19	13	0	0	1	0

